Skip to content
Peptide research

Cortagen

Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

Cortagen is a tetrapeptide bioregulator marketed for brain aging, cognitive support, and nerve repair. The case rests on animal and mechanistic work, reduced neurological deficit and faster nerve regeneration in preclinical models, while cognitive benefit and gene reactivation in humans are speculative. There is no controlled human safety data, and it is contraindicated in pregnancy. Supply is unregulated research-grade product; not FDA-approved.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Cortagen is a synthetic tetrapeptide developed by Professor Vladimir Khavinson, designed using amino acid analysis of Cortexin, a preparation derived from animal brain tissue. Unlike conventional brain-support compounds that work by altering neurotransmitter levels, Cortagen is theorized to act at the genetic level, entering cell nuclei to regulate gene expression in brain and nerve cells. It is studied primarily for nerve regeneration and protection against brain injury.

How it works in the body

A tetrapeptide with proposed gene-regulatory effects. Studies report chromatin changes in cultured human lymphocytes and altered gene expression in mouse heart; specific regulatory-DNA binding and gene normalization in cortical neurons remain unestablished.

Research overview

Cortagen has been studied primarily in Russian preclinical research since the late 1990s. In rats with severed nerves, intramuscular Cortagen injections increased nerve fiber growth rate by 27% and nerve signal speed by 40%. In cultured lymphocytes from older donors, Cortagen altered chromatin condensation; brain rejuvenation was not tested. Gene expression analysis of over 15,000 genes showed Cortagen altered the activity of 110 known genes in heart tissue. In rats with restricted blood flow to the brain, it accelerated behavioral recovery and protected brain tissue from oxidative damage. No randomized controlled human clinical trials exist, and published research comes mainly from Russian institutions, with Georgian and Italian collaborators, and limited independent replication.

Who researches Cortagen?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(8)

Rated by level of concern

  • No human safety data from controlled clinical trials — risk profile is not well characterized

    High

    ClinicalTrials.gov ('cortagen' — 0 studies); PubMed search 'cortagen' — all indexed records preclinical

  • Mild injection-site reactions (redness, swelling) reported anecdotally

    Low

    Anecdotal/vendor reporting; no published AE dataset

  • Contraindicated in pregnancy and breastfeeding due to lack of safety data

    High

    Absence of reproductive toxicology in the PubMed record

  • Patients with severe liver or kidney dysfunction should exercise caution as peptide metabolism/clearance may be altered

    Low

    No published human PK/ADME data

  • Potential for hypersensitivity or allergic reactions in susceptible individuals

    Low

    General parenteral peptide class risk; no Cortagen-specific reports

  • Quality control concerns — as an unregulated research chemical, purity and composition may vary among unregulated products sold online

    High

    No FDA approval; PMID 15159690 / 37042594 / 12447482 all state Ala-Glu-Asp-Pro

  • Long-term effects unknown; no chronic toxicity studies published

    High

    PubMed search 'cortagen' — no toxicology studies

  • Epigenetic gene expression changes could theoretically have unpredictable downstream effects, though none have been documented

    Theoretical

    PMID 15085253; PMID 37042594 (mechanism); no adverse outcome reported

Interaction summary(8)

Rated by direction with this peptide

  • Immunosuppressants and immunomodulators (e.g. calcineurin inhibitors, biologics)

    CautionTheoretical

    Cortagen activated IL-2 mRNA in mouse splenocytes in vitro, though notably more weakly than Vilon or Epithalon, and in the companion study it produced no thymocyte blast-transformation effect at all. Opposing an intentionally suppressed immune state is therefore mechanistically conceivable but rests on weak in vitro signal and has never been tested in a living organism.

    PMID 12447482; PMID 12420072

  • Cortexin (brain cortex polypeptide extract) and other neurotrophic peptide preparations

    NeutralTheoretical

    Cortagen derives from Cortexin's amino acid profile and the two produced comparable neuroprotective and antioxidant effects in the same rat ischemia model. Overlapping rather than additive activity should be assumed — co-use adds redundancy, not established benefit, so this is duplication rather than synergy.

    PMID 21476278

  • Other Khavinson bioregulators (Epitalon, Thymalin, Vilon, Livagen)

    NeutralTheoretical

    These peptides produced the same class effect — ribosomal gene activation and chromatin decondensation — when tested in parallel on lymphocytes from 75–88-year-old subjects, but no combination has ever been studied, so a combined effect is unvalidated rather than demonstrated as safe or synergistic.

    PMID 15085253

  • Cytotoxic chemotherapy and other anti-proliferative or epigenetic therapies (HDAC inhibitors, hypomethylating agents)

    CautionTheoretical

    A compound whose demonstrated action is derepressing condensed chromatin sits in mechanistic tension with therapies designed to control gene expression or proliferation. No oncology co-administration data of any kind exists; this is reasoning from mechanism, not from an observed interaction.

    PMID 37042594; PMID 15085253 (mechanism only)

  • Antiepileptic drugs / patients with seizure disorders

    CautionTheoretical

    Cortagen is CNS-active in animals — it altered behavioral and recovery endpoints in ischemic rats — but no study has measured cortical excitability, seizure threshold, or any interaction with anticonvulsants. Claims that it 'normalizes cortical neurotransmitter gene expression' are not supported by the indexed literature (the only microarray work was in mouse heart), so this entry is precautionary inference only.

    Mechanistic inference from PMID 21476278; no interaction study published

  • Anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin, clopidogrel)

    CautionLow

    No pharmacologic interaction is known; the concern is purely procedural — repeated intramuscular or subcutaneous injection carries higher bruising and hematoma risk in anticoagulated patients.

    Parenteral route-of-administration risk; no PD/PK interaction data for Cortagen

  • Antioxidant and neuroprotective agents (alpha-lipoic acid, N-acetylcysteine, citicoline)

    NeutralTheoretical

    Cortagen reduced lipid-peroxidation products in rats, but in that same study serum and cortical antioxidant activity fell rather than rose, so an additive antioxidant effect cannot be assumed in either direction. No combination study exists; treat as unstudied rather than synergistic.

    PMID 21476278; PMID 18239817

  • Cholinesterase inhibitors and nootropics (donepezil, piracetam)

    NeutralTheoretical

    Different mechanistic targets — cholinergic transmission versus chromatin-level gene regulation — with no known metabolic or receptor-level conflict, though no co-administration has been studied.

    Mechanistic reasoning; no published interaction data

Known risks(8)

  • No human safety data from controlled clinical trials — risk profile is not well characterized

  • Mild injection-site reactions (redness, swelling) reported anecdotally

  • Contraindicated in pregnancy and breastfeeding due to lack of safety data

  • Patients with severe liver or kidney dysfunction should exercise caution as peptide metabolism/clearance may be altered

  • Potential for hypersensitivity or allergic reactions in susceptible individuals

  • Quality control concerns — as an unregulated research chemical, purity and composition may vary among unregulated products sold online

  • Long-term effects unknown; no chronic toxicity studies published

  • Epigenetic gene expression changes could theoretically have unpredictable downstream effects, though none have been documented

Drug interactions(6)

  • note

    No formal drug interaction studies have been conducted for Cortagen. The following are theoretical considerations based on mechanism of action.

  • Anticoagulants/Antiplatelets

    Aspartic acid (Asp) in the sequence may theoretically have mild effects on coagulation pathways. Exercise caution with warfarin, heparin, or aspirin.

  • Immunosuppressants

    Cortagen modulates immune cell gene expression. Theoretical interaction with cyclosporine, tacrolimus, or corticosteroids that also affect immune function.

  • Other neuropeptides/nootropics

    No adverse interactions with Epitalon, Thymalin, Semax, or Selank have been reported, and formal interaction studies are lacking.

  • Antiepileptic drugs

    Cortagen affects neuronal gene expression and could theoretically interact with drugs like carbamazepine or valproic acid that also modulate gene expression.

  • general_caution

    Due to the absence of pharmacokinetic and pharmacodynamic interaction studies, caution is warranted when combining Cortagen with any medication.

Research & benefits

Evidence base

Total Studies
0
Human Studies
0

PRECLINICAL ONLY — No FDA-approved human clinical trials exist for Cortagen. The evidence base is limited to: (1) In vivo animal studies in rats and mice demonstrating nerve regeneration, neuroprotection from ischemia, gene expression modulation, and behavioral recovery. (2) In vitro/ex vivo studies on chromatin remodeling and epigenetic regulation. (3) Limited human observational reports from Russian clinical practice noting "pronounced therapeutic effects" on posttraumatic peripheral nerve recovery and cardiovascular/cerebrovascular parameters, but these lack the rigor of double-blind placebo-controlled trials. The overall evidence level is LOW by Western clinical standards. Published research includes Russian institutions, a Georgian chromatin study, and Italian–Russian collaboration. Independent replication by Western research groups is absent.

Researched for(6)

Rated by confidence in the evidence

  • Neuroprotection — reduces neurological deficit and supports brain tissue recovery after ischemic injury in animal models

    Low

    Single rat study found faster ischemic recovery and reduced oxidative stress, not independently replicated.

    PMID 21476278 (Eksp Klin Farmakol 2011)

  • Peripheral nerve regeneration — significantly enhances nerve fiber growth rate (+27%) and conduction velocity (+40%) post-injury

    Low

    Rat studies show faster nerve fiber growth and conduction recovery, but no controlled human trials exist.

    PMID 11276314 (Bull Exp Biol Med 2000); PMID 12134478 (Dokl Biol Sci 2002)

  • Epigenetic rejuvenation — induces deheterochromatinization of aged chromatin, potentially reactivating age-silenced genes

    Low

    Human leukocyte studies show chromatin decondensation with age, but no clinical rejuvenation outcome demonstrated.

    PMID 15085253 (Bull Exp Biol Med 2004); PMID 37042594 (Georgian Med News 2023)

  • Antioxidant support — prevents excessive lipid peroxidation and maintains antioxidant enzyme activity in brain tissues

    Low

    Preclinical studies conflict: one preserved antioxidant activity in ischemic rats, another found it suppressed.

    PMID 21476278 (ischemic rat model, antioxidant activity preserved); PMID 18239817 (non-ischemic rats, antioxidant activity suppressed)

  • Gene expression modulation (110+ genes altered in a mouse heart-tissue study)

    Speculative

    One female-mouse heart study found 110 genes altered; neural and immune effects unverified.

    PMID 15159690 (Neuro Endocrinol Lett 2004) — female CBA mouse heart cDNA microarray only, 5-day dosing, single non-replicated study. No source exists for gene-expression effects of Cortagen in neural or immune tissue.

  • Cognitive support — studied for potential improvements in cognitive performance through neural repair and cellular resilience

    Speculative

    Inferred from rat ischemia recovery data only; no human cognitive trials have been conducted.

    PMID 21476278; ClinicalTrials.gov search 'cortagen' — no registered studies

Benefits(7)

  • Neuroprotection — reduces neurological deficit and supports brain tissue recovery after ischemic injury in animal models

  • Peripheral nerve regeneration — significantly enhances nerve fiber growth rate (+27%) and conduction velocity (+40%) post-injury

  • Epigenetic rejuvenation — induces deheterochromatinization of aged chromatin, potentially reactivating age-silenced genes

  • Antioxidant support — prevents excessive lipid peroxidation and maintains antioxidant enzyme activity in brain tissues

  • Gene expression modulation (110+ genes altered in a mouse heart-tissue study)

  • Anti-inflammatory potential — reported to reduce neuroinflammation and modulate autoimmune reactions in preclinical models

  • Cognitive support — studied for potential improvements in cognitive performance through neural repair and cellular resilience

Key studies(5)

  1. Turchaninova LN, Kolosova LI, Malinin VV, Moiseeva AB, Nozdrachev AD, Khavinson VK

    Bulletin of Experimental Biology and Medicine

    2000

    Intramuscular cortagen (10 mcg/kg for 10 days) increased sciatic nerve fiber growth rate by 27% and conduction velocity by 40% in rats after nerve transection and suturing.

  2. Anisimov SV, Khavinson VKh, Anisimov VN

    Neuro Endocrinology Letters

    2004

    Microarray analysis of 15,000+ transcripts revealed Cortagen altered expression of 234 clones (110 known genes) in mouse heart, with maximum fold changes of +5.42 (upregulation) and -2.86 (downregulation).

  3. Zarubina IV, Shabanov PD

    Eksperimentalnaia i Klinicheskaia Farmakologiia

    2011

    Cortagen accelerated behavioral recovery in ischemic rats, prevented excessive lipid peroxidation, and maintained antioxidant activity in brain tissues. Authors concluded cortagen can increase efficacy of neuroprotective therapy in chronic brain ischemia.

  4. Lezhava T, Monaselidze J, Jokhadze T, Gaiozishvili M

    International Journal of Peptide Research and Therapeutics

    2015

    Cortagen induced deheterochromatinization of total heterochromatin, activated ribosomal gene synthesis via decondensation of satellite stalks of acrocentric chromosomes, and released repressed genes from facultative heterochromatin — showing chromatin changes in cultured lymphocytes, without demonstrating clinical rejuvenation.

  5. Zarubina IV, Shabanov PD

    Bulletin of Experimental Biology and Medicine

    2016

    Peptide preparations including Cortagen reduced severity of neurological deficit, restored individual behavior structure, and demonstrated antioxidant action during chronic ischemic brain damage in rats during early and late phases of ischemic preconditioning.

Regulation & availability

Why researchers look at it

Animal studies showed a 27% increase in nerve fiber growth and 40% faster nerve signal transmission after injury, with gene expression changes across 110 known genes — with separate chromatin experiments conducted in cultured lymphocytes. Research is mainly preclinical and includes Italian–Russian collaboration; clinical benefits remain unconfirmed, but the proposed epigenetic mechanism is distinct from any existing neuroprotective approach.

Estimated cost
$30-80/mo oral capsules
FDA status
Cortagen is not FDA-approved for any indication. No publicly disclosed Cortagen IND was identified; public databases cannot establish whether an IND is on file. Cortagen is absent from the reviewed FDA 503A and 503B nomination categories, and no routine bulk-compounding basis was verified. Absence of a Cortagen-specific enforcement action does not establish lawful human therapeutic marketing.
WADA status
Cortagen is not named. S0 prohibits at all times pharmacological substances not covered by later sections of the List that lack current approval by any governmental health authority for human therapeutic use. S2 is not a blanket peptide prohibition.
Prescribability
No — not FDA-approved Not approved for human clinical use by any major regulatory authority.
Availability
In Russia, Cortexin (the parent polypeptide from which Cortagen was derived) is an approved pharmaceutical, but the isolated synthetic tetrapeptide Cortagen itself is not a registered drug in any major regulatory jurisdiction.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(9)

  1. 1990s
    Vladimir Khavinson develops Cortexin (bovine brain cortex polypeptide extract) at the Saint Petersburg Institute of Bioregulation and Gerontology
  2. 1990s
    Cortagen tetrapeptide (Ala-Glu-Asp-Pro) synthesized using amino acid analysis of Cortexin.
  3. 2000
    First published preclinical study — sciatic nerve regeneration in rats (Turchaninova et al., PMID: 11276314)
  4. 2004
    Gene expression microarray study published demonstrating broad transcriptional effects in mouse heart (Anisimov et al., PMID: 15159690)
  5. 2011
    Study on Cortagen in chronic brain ischemia published (Zarubina & Shabanov, PMID: 21476278)
  6. 2015
    Epigenetic regulation of aged heterochromatin study published (Khavinson & Linkova, DOI: 10.1007/s10989-014-9443-7)
  7. 2016
    Neuroprotective effects during ischemic preconditioning study published (Zarubina & Shabanov, PMID: 26902350)
  8. 2020
    No regulatory approval sought or obtained in any Western jurisdiction.
  9. 2026
    Not FDA-approved. No publicly disclosed active IND identified; confidential filing status is unknown. Cortexin (parent compound) remains an approved pharmaceutical in Russia.

Sources & FAQs

Research sources(7)

Frequently asked questions(4)

What is the difference between Cortagen and Cortexin?

Cortexin is a complex polypeptide mixture extracted from bovine brain cortex, approved as a pharmaceutical in Russia. Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide designed using amino acid analysis of Cortexin; the cited work does not establish it as Cortexin's primary active component. Cortagen is a single defined-sequence peptide, while Cortexin contains many peptide fractions.

Is there human clinical trial data for Cortagen?

No randomized controlled human clinical trials have been published for Cortagen. Evidence is limited to animal studies and observational reports from Russian clinical practice. The human data that does exist describes therapeutic effects on peripheral nerve recovery but lacks the rigor of placebo-controlled trials.

How is Cortagen typically administered in research?

In published animal studies, Cortagen was administered via intramuscular injection. Some sources mention intranasal and oral capsule formulations.

Is Cortagen the same as other brain peptides like Semax or Selank?

No. Cortagen is a bioregulatory peptide that works at the epigenetic level to modulate gene expression. Semax and Selank are synthetic analogs of natural neuropeptides (ACTH and tuftsin, respectively) that work primarily through neurotransmitter modulation. They have different mechanisms, sequences, and evidence bases.